tiprankstipranks
Neuren’s Trial Suggests Breakthrough in Angelman Syndrome
Company Announcements

Neuren’s Trial Suggests Breakthrough in Angelman Syndrome

Neuren Pharmaceuticals Limited (AU:NEU) has released an update.

Pick the best stocks and maximize your portfolio:

Neuren Pharmaceuticals Limited has reported promising results from a Phase 2 clinical trial for NNZ-2591, a treatment for Angelman syndrome, showing significant improvements in patient behaviors and cognitive function. The trial demonstrated that the drug was safe and well-tolerated in children, with meaningful advancements observed in communication, behavior, cognition, and motor abilities. The findings bolster confidence in NNZ-2591’s potential to treat a range of neurodevelopmental disorders.

For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskNeuren Pharmaceuticals Announces Share Buy-Back Program
TipRanks Australian Auto-Generated NewsdeskNeuren Pharmaceuticals Boosts Buy-Back Program
TipRanks Australian Auto-Generated NewsdeskNeuren Pharmaceuticals Gains from Acadia’s $150M Voucher Sale
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App